Thomson Scientific Launches Thomson Innovation

The Thomson CorporationThomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, has launched its new intellectual property research and analysis solution, Thomson Innovation. For the first time, researchers will be able to simultaneously search worldwide editorially enhanced patent data, Asian patent data translated into English, scientific literature, and business and news sources.

"The global intellectual property market is changing rapidly, and organizations need to be aware of changes in the evolving landscape, such as the proliferation of patenting activity in Asia," said David Brown, Executive Vice President, Corporate Markets, Thomson Scientific. "It's more critical than ever for our customers to have access to the most authoritative patent data, and to incorporate complementary sources, like scientific literature, in their intellectual property research."

Designed in collaboration with more than 1,800 customers, Thomson Innovation sets a new standard in intellectual property research and analysis that will help companies accelerate ideation, improve productivity, minimize risks and gain a competitive advantage. It provides:

  • Comprehensive prior art searching with the ability to search patents and scientific literature simultaneously
  • Expanded Asian patent coverage, including translations of Japanese full-text and additional editorially enhanced abstracts of Chinese data
  • A fully integrated searchable database combining Derwent World Patent Index® (DWPISM) with full-text patent data to provide the most comprehensive patent records available
  • Support of strategic intellectual property decisions through:
    • powerful analysis and visualization tools, such as charting, citation mapping and search result ranking
    • and, integration of business and news resources
  • Enhanced collaboration capabilities, including customizable folder structures that enable users to organize, annotate, search and share relevant files

Thomson Innovation is being launched in phases, and the first release is available now and includes global, full-text patent sources, including Japan. In rapid succession, it will be followed by the addition of Derwent World Patents Index, scientific literature, business information and news. A series of additional enhancements will be delivered throughout 2008.

For more information about Thomson Innovation, visit www.thomsoninnovation.com.

About The Thomson Corporation
The Thomson Corporation is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation’s common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC). Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development—from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at http://scientific.thomson.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...